Re-rated 2026-07-03: Valuation on the new warranted-multiple anchor. 30× clean is above the 22× pharma guardrail floor → BUY/STRONG BUY → HOLD across horizons. GLP-1 growth remains the bull case; the disciplined anchor caps the price. Quality unchanged.
Horizon signals reshuffled — driven entirely by a macro sector flip, not by Lilly's fundamentals. The latest Macro-Economic report (2026-06-20) flipped Health Care (XLV) from Short O / Medium O / Long N to Short U / Medium N / Long O — healthcare rotated out of near-term favour and into long-term favour. Result: Short STRONG BUY → BUY, Medium STRONG BUY → BUY (the short/medium Tailwind that had amplified them is gone), and Long BUY → STRONG BUY (Long XLV Outperform + GLP-1 driver 82 now amplifies). Price −2.2% ($1,122.50 → $1,098.13).
Lifecycle — Large-cap pharma in an accelerated-growth phase. Q1 2026 revenue grew +55.5% YoY to $19.8B, powered by Mounjaro and Zepbound (tirzepatide). TTM revenue ~$72.2B, net income ~$25.3B, with a pipeline (orforglipron oral GLP-1, retatrutide) that extends the runway. We use the Healthcare/Pharma profile (R&D efficiency, patent-cliff exposure, pipeline depth) layered with the hyper-growth lens.
| Sub-signal | Value | Benchmark | Score | Read |
|---|---|---|---|---|
| Revenue trajectory | +55.5% YoY | Big-pharma ~5–8% | 95 | GLP-1 hyper-growth; Mounjaro +125%, Zepbound +80% |
| Profitability | GM 83.5% · Op 45.9% · Net 35% | Pharma GM ~75% | 88 | Best-in-class margins; operating earnings clean |
| ROE / ROIC | ROE 81%; ROIC ~92nd pct | Top-decile | 92 | Exceptional capital efficiency |
| Balance sheet | Int. coverage 37.5x; D/E 1.39 | Coverage >5x healthy | 78 | Levered for capacity build-out but easily serviced |
| Competitor | Type | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| Novo Nordisk (NVO) | Direct GLP-1 rival | Lilly gaining — tirzepatide 20.2% vs semaglutide 13.7% weight loss; NVO −67% from peak | Price war: NVO cut Wegovy oral to $149/mo (volume-over-price) |
| Pfizer / Viking (VK2735) / Amgen MariTide / Roche | Next-wave entrants | Pre-launch; Lilly ahead | Long-term pricing-power erosion as orals/competitors proliferate |
| US drug-pricing policy | Regulatory / structural | Overhang, undated | Medicare negotiation / MFN could compress net pricing |
Net effect on moat: Switching Costs held at 55 (no real lock-in — efficacy retains, not contracts) and Pricing Power trimmed to 70 (the $149 Novo pill + policy cap the ceiling); Cost Advantage stays high at 75 on the manufacturing lead. → moat 69. The competitive thesis propagates to the Bear scenario (§11) and the §12 thesis-invalidation rule.
ROIC sits in the ~92nd percentile of pharma. Capital allocation scored 80 — aggressive, mostly value-accretive reinvestment into GLP-1 manufacturing capacity and tuck-in pipeline M&A (e.g. Adverum for wet-AMD gene therapy), plus a modest dividend (~0.6% yield). Management skin-in-the-game scored 50 (professional management, limited insider ownership typical of a 150-year-old large cap).
Lilly is a premium-priced compounder. At $1,098.13 (off ~7% from the $1,182.73 52-week high) it trades on a rich absolute multiple. Under the new warranted-multiple anchor the score is Expensive (36): a clean 30× P/E sits above both the ~23× warranted multiple and the 22× per-sector guardrail floor — the exceptional GLP-1 growth is the bull argument, but the disciplined sector cap keeps the price ahead of what the anchor warrants.
| Multiple | Current | Context | Read |
|---|---|---|---|
| Trailing P/E | ~39x | Decile ~5 of own 5-yr range | Rich, not extreme |
| Forward P/E (FY26 / FY27) | 30.0x / 24.7x | Consensus EPS $36.6 → $44.5 | De-rates fast on growth |
| PEG (forward) | ~1.8 | EPS CAGR FY26→FY30 ~14.9% | Fair for the quality |
| FCF yield | ~1.3% | Depressed by capacity capex | Expensive on cash today |
Analyst consensus: 45 analysts, Buy (33 Buy / 9 Hold / 3 Sell; 73.3% bullish), 0 upgrades & 0 downgrades in 30 days (all 'maintain'). Consensus target $1,271 (+15.8% from spot), median $1,280, range $1,119–$1,400. Last-month fresh average $1,240. FMP health rating B (3/5): ROE 5 / ROA 5 / DCF 4 strong; P/E 1, P/B 1, D/E 1 reflect the premium valuation. Price now sits ~16% below consensus, but consensus targets are not the anchor here — the warranted multiple is.
Net → Expensive → HOLD. A superb franchise with exceptional GLP-1 growth, but a rich price under the disciplined warranted-multiple anchor: clean 30× is above both the ~23× warranted multiple and the 22× pharma guardrail floor, so Valuation scores 36 (Expensive) and the strong (82) driver can no longer amplify — the base HOLD stands across all horizons.
Lilly's fortunes are dominated by one external force: the incretin (GLP-1 / GIP) obesity-and-diabetes super-cycle — a multi-hundred-billion-dollar TAM still in early innings. We score demand, Lilly's competitive position within it, and the forward pipeline.
| Horizon | Read | Detail |
|---|---|---|
| Historical (25%) | Very strong | Mounjaro/Zepbound drove +55% revenue growth; the franchise built the category |
| Current (50%) | Strong tailwind | Tirzepatide out-performs semaglutide on efficacy; Lilly is winning share and has a manufacturing-capacity lead; GLP-1 market forecast ~12% CAGR to ~$95B by 2035 |
| Forward (25%) | Strong | Orforglipron oral (Phase-3 positive, 2026 decision) + retatrutide next-gen extend leadership; offset modestly by pricing pressure (Novo $149 pill, US policy) |
Driver score 82 — Strong Tailwind, amplification-eligible (≥65) on its own metric. Normally, combined with a supportive economic pressure, it could lift a base BUY to STRONG BUY. That amplification is now blocked: Valuation has re-rated to Expensive (36) under the disciplined warranted-multiple anchor, and a strong driver cannot amplify a name in the Expensive band. The base signal is HOLD across all three horizons; the 82 driver is real and is the bull argument, but the rich price caps the signal rather than lifting it. The GLP-1 super-cycle remains the reason to hold (not sell) through near-term noise.
Lilly isn't a named watchlist line in the latest Macro-Economic report (2026-06-20), so we map its GICS Health-Care sector to the Driver-Sector matrix: XLV = Short U / Medium N / Long O. This is a notable flip from the prior report's XLV = O / O / N — healthcare has rotated OUT of near-term favour (sector-rotation into other groups + the drug-pricing overhang) but moved INTO long-term favour. Anchoring the card on the Medium horizon gives Neutral pressure (conviction 52). Per-horizon the macro pressure reads Short = Headwind (XLV U), Medium = Neutral (XLV N), Long = Tailwind (XLV O). Normally the Long Tailwind plus the GLP-1 driver at 82 would amplify a base BUY to STRONG BUY — but the 2026-07-03 valuation re-rate makes the base signal HOLD (Expensive on the warranted-multiple anchor: clean 30× above the 22× guardrail floor), and amplification is blocked in the Expensive band, so no horizon lifts above HOLD. The macro sector map is unchanged; it simply no longer has a BUY to amplify. Lilly's own quality (84) and driver (82) are likewise unchanged — the mover is the valuation methodology, not the fundamentals.
Source: sector-map · Macro report 2026-06-20
Timing is constructive: the monthly/weekly/daily trends are all up and the pullback is confined to intraday timeframes — the textbook 'buy-the-dip in an uptrend'. The two checks on the score are the near-52-week-high extension and softening daily momentum.
| Sub-signal | Read | Detail |
|---|---|---|
| MTF trend score | ~66 — bullish | Monthly/weekly uptrend, daily strong uptrend; hourly/15-min pulling back |
| Risk-reward | ~48 | ~10% to the $985 stop; daily ATR ~$35 (3.1%) |
| Relative strength | ~88 — strong leader | 3-mo +20.6% vs SPY +14.9% & XLV +2.8% (outperforms both); 1-mo +7.8% vs SPY +0.7% |
| 52-wk range position | ~85% (near highs) | Extended — momentum, not value |
| Sentiment (analyst grades) | Buy, all 'maintain' | 0 up / 0 down in 30 days; recent news tone strongly positive (healthcare-rebound leader) |
| Catalyst clustering | 70 — calm | No clustered events; orforglipron decision undated |
Dynamic macro weight 0.10 (defensive-pharma low sensitivity). RSI daily 54 (cooled from ~62, healthy), monthly 64. The pullback to the 20-day (~$1,107) within a strong uptrend is the entry zone; momentum buyers want a daily MACD turn back up to confirm.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-06-23 | US Flash PMIs (Jun) | Medium | Comp ~50.8 | 51.5 | Low | Defensive pharma — minimal direct sensitivity |
| 2026-06-25 | US Core PCE MoM (May) | Medium | +0.2% | +0.2% | Low | Fed path; growth-stock multiple read |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-06-17 | FOMC Projections (hawkish dot-plot) | — | 2026 hike median | — | Mild headwind to high-multiple growth names broadly |
| 2026-06-18 | Initial Jobless Claims | 226K | 225K | Neutral — labour steady |
Lilly has low macro sensitivity (healthcare is a Low macro-sensitivity sector). No high-impact, pharma-specific economic release sits in the next 14 days. The relevant 'events' for Lilly are drug-specific (orforglipron approval, undated) and policy (drug-pricing), not the economic calendar. No WAIT-for-event override applies.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend | Bullish | 64.0 | +102, rising | S: $623 R: $1,134 | Resist. breakout | 0.58x |
| Weekly | Uptrend | Bullish | 60.6 | +40, hist + | S: $623 / $709 R: $1,114 | Resist. breakout | 0.79x |
| Daily | Strong Uptrend | Bullish | 54.0 | +31, hist − | S: $877 (SMA50 $1,001) R: $1,149 / $1,183 | Resist. breakout | 1.37x |
| Hourly | Strong Downtrend | Bearish | 39.8 | −4, hist + | S: $1,089 R: $1,146 | Support breakdown | — |
| 15-min | Strong Downtrend | Bearish | 47.3 | −0.2 | S: $1,089 R: $1,125 | — | — |
| Confluence: Bullish (higher-TF uptrend, lower-TF pullback) · MTF Score 66 | |||||||
Monthly, weekly and daily are all in uptrends (the daily strongly so), with the only weakness on the hourly/15-minute — a classic higher-timeframe-bullish + lower-timeframe-pullback 'buy-the-dip' structure. Price is resting on the 20-day (~$1,107) and well above the 50-day ($1,001) and 200-day ($966). The $877–$888 weekly support is the line that matters on any deeper flush; the $1,182.73 52-week high is the resistance to clear for a new leg.
LLY — 6-month daily close (USD). Strong uptrend off the March $851 low to the June $1,183 high, now in an orderly pullback to the 20-day; well above the 50-/200-day.
Orforglipron oral launches into a massive, manufacturing-light TAM; retatrutide data confirms next-gen leadership; GLP-1 share gains continue and policy risk stays benign. Re-rates toward the $1,400 high target.
Tirzepatide growth moderates but stays strong, the pipeline advances on schedule, and the multiple holds as EPS compounds ~15%. Meets the median analyst target over 12 months. Probability-weighted centre of gravity.
Competitive/pricing trigger: Novo's $149 pill plus next-wave entrants (Pfizer, Viking, Amgen) compress GLP-1 pricing, and/or US drug-pricing policy bites — net pricing and the premium multiple both de-rate. Falls back toward the 200-day region.
Probability-weighted ~$1,235 (Bull 30% · Base 50% · Bear 20%) — ~+12% over 12 months. The Bear case is explicitly competitive/regulatory (the named GLP-1 rivals + drug-pricing policy), consistent with the elevated competitive-threat read in §3 — a live downside path, not a tail.
Forecast: Fundamental group: now not MET — the Expensive re-rate (30× vs ~23× warranted, above the 22× floor) closes the valuation entry path; it would re-open on a meaningful de-rate toward the warranted multiple. Technical group: the 50-/200-day reclaim is long done; the missing piece is a momentum turn — a daily MACD-histogram flip back positive as the intraday pullback exhausts near the 20-day (~$1,107) / $1,089 support. At the current pullback pace that is plausibly ~1–2 weeks out — CONFIDENCE: Moderate-High, given the intact higher-timeframe uptrend and strong relative strength. Catalyst group: catalyst-dependent — the undated orforglipron approval and Q2 earnings (~early Aug) are the triggers; not time-projectable.
Forecast: Stop-Loss: Unlikely in the next 4–6 weeks — $985 is ~10% below spot and below both the 50- and 200-day; it would need a competitive/policy shock or a broad risk-off. Thesis Invalidation: not live, but the competitive condition is the one to watch (Novo pricing, next-wave data). Profit-Target: ~17% away to the base target.
What you're risking: you're buying near 52-week highs (~85% of range) mid-pullback at a clean 30× P/E that is Expensive vs the ~23× warranted multiple and the 22× pharma guardrail floor; daily momentum is still soft, a deeper dip to the $1,001 50-day is on the table, and the bear case (competitive/pricing) would take it toward $900. What you're gaining: the GLP-1 secular leader (driver 82) with a manufacturing-capacity moat and free optionality on orforglipron/retatrutide — the bull argument, but one the rich price already discounts. Read: the signal is HOLD and the conviction ladder reads Wait — there is no entry edge here today; a better-priced entry opens on a de-rate toward the warranted multiple or a confirmed momentum turn.
What you'd give up: the GLP-1 secular franchise (driver 82), the orforglipron/retatrutide optionality, and a top-decile-ROIC business. What you'd protect: only the ~18% downside if competition/policy bites, plus the premium-multiple risk that the Expensive read flags. Read: no exit rule is live — no stop hit, no thesis break, no profit-target — and Quality is unchanged at 84, so this is a hold. The Expensive re-rate argues against adding, not against holding; trim only into the $1,280+ zone on an overbought print.
No allocation or portfolio role was specified, so position sizing is not computed. The §12 Conviction Ladder reads Wait (0 of 3 entry paths met — the Expensive re-rate closes the fundamental path): no new entry is framework-consistent here, so an existing holder holds (Quality 84, no exit trigger live) while a new buyer waits for a de-rate toward the warranted multiple or a confirmed momentum turn. Volatility context: daily ATR ~$35 (~3.1%), beta ~0.52 (notably less volatile than the market), 52-week range $623.78–$1,182.73. The drug-pricing overhang argues for sizing with that policy tail in mind.
{
"ticker": "LLY",
"exchange": "NYSE",
"exchange_ticker": "NYSE:LLY",
"isin": "US5324571083",
"cusip": "532457108",
"date": "2026-06-22",
"version": "v6",
"company": "Eli Lilly and Company",
"sector": "Healthcare / Pharmaceuticals (Drug Manufacturers - General)",
"lifecycle_stage": "large_cap_pharma_accelerated_growth",
"user_context": {
"horizon": null,
"allocation_pct": null,
"portfolio_role": null
},
"price_at_rating": 1098.13,
"market_cap_usd": 1006000000000,
"shares_outstanding_diluted_m": 895.9,
"beta": 0.517,
"dividend_yield_pct": 0.59,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": null,
"base_signal_all_horizons": "HOLD",
"amplification_note": "Base HOLD all horizons: High Quality (84) + Expensive Valuation (36) -> HOLD. Clean 30x is above the 22x Health-Care guardrail floor (and ~1.30x the ~23x warranted multiple), so the strong driver (82) can no longer amplify -> STRONG BUY amplification blocked in the Expensive band.",
"composite_short": 52,
"composite_medium": 55,
"composite_long": 60,
"quality_score": 84,
"quality_detail": {
"industry_benchmark_name": "R&D Efficiency + Patent-Cliff Exposure (pharma)",
"industry_benchmark_score": 88,
"moat_score": 69,
"moat_pricing_power": 70,
"moat_network_effects": 55,
"moat_switching_costs": 55,
"moat_cost_advantage": 75,
"moat_intangibles": 90,
"roic_percentile_vs_peers": 92,
"capital_allocation": 80,
"management_skin_in_game": 50,
"revenue_yoy_q1_2026_pct": 55.5,
"ttm_revenue_usd": 72249500000,
"ttm_net_income_usd": 25275000000,
"ttm_operating_income_usd": 33137600000,
"gross_margin_ttm_pct": 83.5,
"operating_margin_ttm_pct": 45.9,
"net_margin_ttm_pct": 35.0,
"roe_ttm_pct": 81,
"interest_coverage_x": 37.5
},
"valuation_score": 36,
"warranted_multiple": 23,
"actual_multiple": 30,
"val_multiple_basis": "clean P/E",
"discount_rate_r": 9.0,
"risk_free_10y": 4.48,
"g_near": 10,
"g_term": 3,
"warranted_ratio": 1.30,
"val_band": "expensive",
"valuation_detail": {
"trailing_pe": 39.0,
"forward_pe_fy2026": 30.0,
"forward_pe_fy2027": 24.7,
"p_b": 31.5,
"p_s_ttm": 14.3,
"fcf_yield_pct": 1.3,
"peg_forward": 1.8,
"implied_growth_rate_pct": 15.0,
"consensus_eps_cagr_fy26_fy30_pct": 14.9,
"historical_valuation_decile": 5,
"embedded_optionality_tilt": "+2 (orforglipron oral, retatrutide, oncology Jaypirca, Alzheimer's Kisunla, Adverum wet-AMD gene therapy)"
},
"timing_score": 58,
"timing_detail": {
"mtf_confluence_score": 66,
"mtf_label": "Bullish (higher-TF uptrend + lower-TF pullback)",
"mtf_pattern": "Higher-TF bullish + lower-TF pullback -> buy-the-dip",
"risk_reward_score": 48,
"relative_strength_vs_spy_3m": "outperform_strong (+20.6% vs +14.9%)",
"relative_strength_vs_sector_3m": "outperform_strong (vs XLV +2.8%)",
"catalyst_clustering_score": 70,
"dynamic_macro_weight": 0.1,
"rsi_daily": 54.0,
"rsi_monthly": 64.0,
"atr_daily": 34.6,
"sma50_daily": 1000.66,
"sma200_daily": 966.09,
"pct_52w_range": 85,
"week_52_high": 1182.73,
"week_52_low": 623.78
},
"driver_score": 82,
"driver_label": "Strong Tailwind",
"driver_name": "GLP-1 / obesity-and-diabetes incretin franchise (TAM demand + pipeline + manufacturing capacity vs Novo Nordisk)",
"driver_amplification_eligible": true,
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 52,
"economic_alignment_pressure": "Neutral",
"economic_alignment_pressure_by_horizon": {
"short": "Headwind",
"medium": "Neutral",
"long": "Tailwind"
},
"economic_alignment_source": "sector-map",
"economic_alignment_sector": "Healthcare (XLV) s=U / m=N / l=O",
"macro_report_date": "2026-06-20",
"overall_confidence": 72,
"confidence_detail": {
"quality": 80,
"valuation": 85,
"timing": 72,
"driver": 70,
"economic_alignment": 60
},
"fair_value_est": 1150,
"stop_loss": 985,
"target_price": 1280,
"scenario_base_target": 1280,
"scenario_bull_target": 1400,
"scenario_bear": 900,
"analyst_consensus_target": 1271.24,
"analyst_target_high": 1400,
"analyst_target_low": 1119,
"analyst_target_median": 1280,
"analyst_target_upside_pct": 15.8,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 73.3,
"analyst_coverage_count": 45,
"fmp_rating": "B",
"fmp_overall_score": 3,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"nonop_pct_of_net_income": -8,
"clean_pe": 30.0,
"clean_peg": 1.8,
"competitive_share_trajectory": "gaining",
"competitive_threat_level": "elevated",
"hard_gate_state": "caution",
"gates_triggered": [],
"gates_caution": [
"Valuation ceiling: clean 30x above the 22x Health-Care guardrail floor (and ~1.30x the ~23x warranted multiple) -> caps signal at HOLD",
"US drug-pricing policy (Medicare/MFN) overhang",
"orforglipron approval undated 2026",
"intensifying GLP-1 competition"
],
"do_not_buy_triggers": [],
"entry_groups_met": 0,
"entry_conviction": "Wait",
"exit_groups_live": 0,
"exit_action": "Hold",
"key_catalyst": "Q2 2026 earnings ~early Aug; orforglipron approval (undated 2026); retatrutide data",
"next_update_date": "2026-07-06",
"next_update_basis": "default +14d (no impactful dated catalyst in window; Q2 earnings ~early Aug, orforglipron undated)",
"analysis_status": "on-going",
"finder_ticker": "LLY",
"finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NYSE",
"section": "Defensive Health Care",
"report_filename": "LLY_Signal_v6_20260622_1305.html"
}
Short HOLD · Medium HOLD · Long HOLD. Re-rated 2026-07-03 on the new warranted-multiple anchor: clean 30× is Expensive vs the ~23× warranted multiple and above the 22× Health-Care guardrail floor, so Valuation steps 52 → 36 and the strong (82) driver can no longer amplify — BUY/BUY/STRONG BUY all step to HOLD. Quality unchanged (84), Driver unchanged (82 Strong Tailwind — the bull case, but the disciplined anchor caps the price). No Do-Not-Buy triggers; the Valuation Ceiling is now a sizing caution. Conviction Ladder: Wait.